DSP5336 is an oral small molecule inhibitor of menin and MLL protein interaction. DSP5336 is undergoing clinical evaluation for its use in the treatment of patients with Relapsed or Refractory Acute Leukemia.

Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity.

RIG012 is a potent antagonist of Retinoic Acid Inducible Gene 1 (RIG-I), an innate immune receptor, with an IC50 of 0.71 μM in the NADH-coupled ATPase assay. It effectively blocks RIG-I-initiated signaling and inflammatory responses induced by SARS-CoV-2 RNA.

RIG012 is a potent antagonist of Retinoic Acid Inducible Gene 1 (RIG-I), an innate immune receptor, with an IC50 of 0.71 μM in the NADH-coupled ATPase assay. It effectively blocks RIG-I-initiated signaling and inflammatory responses induced by SARS-CoV-2 RNA.

RIG012 is a potent antagonist of Retinoic Acid Inducible Gene 1 (RIG-I), an innate immune receptor, with an IC50 of 0.71 μM in the NADH-coupled ATPase assay. It effectively blocks RIG-I-initiated signaling and inflammatory responses induced by SARS-CoV-2 RNA.

RIG012 is a potent antagonist of Retinoic Acid Inducible Gene 1 (RIG-I), an innate immune receptor, with an IC50 of 0.71 μM in the NADH-coupled ATPase assay. It effectively blocks RIG-I-initiated signaling and inflammatory responses induced by SARS-CoV-2 RNA.

Benzo[a]pyrene (3,4-Benzopyrene) is classified as “probably carcinogenic to humans” (Group 2A), exhibits lung carcinogenicity in animal models. It is frequently used in chemoprevention studies and two-stage carcinogenesis models.

Pyrithione, a Transition metal complexe, is a zinc ionophore that causes increased zinc levels within mammalian cells. Pyrithione has potent bactericidal and anti-fungal activity.

Cycloleucine is a specific antagonist of NMDA receptor(N-methyl-D-aspartate receptor coupled glycine receptor), with a Ki of 600 μM. Cycloleucine also acts as a specific inhibitor of S-adenosyl-methionine-mediated methylation. Cycloleucine exhibits cytostatic effects.

Cycloleucine is a specific antagonist of NMDA receptor(N-methyl-D-aspartate receptor coupled glycine receptor), with a Ki of 600 μM. Cycloleucine also acts as a specific inhibitor of S-adenosyl-methionine-mediated methylation. Cycloleucine exhibits cytostatic effects.